A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)
Ravi Vij(Washington University in St. Louis), Steven M. Devine(National Marrow Donor Program), Kouros Owzar(Duke University), Luis Isola(Mount Sinai Medical Center), Kristina Laumann(Goethe University Frankfurt), Tsiporah B. Shore(Cornell University), Frank Beardell(Christiana Care Health System), Jennifer Le‐Rademacher(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Margarida Magalhaes‐Silverman(University of Iowa Hospitals and Clinics), Kenneth R. Meehan(Dartmouth–Hitchcock Medical Center), Thomas C. Shea(University of North Carolina at Chapel Hill), Amanda F. Cashen(MACOM (United States)), Vera Hárs, David D. Hurd(Duke University), Sumithira Vasu(The Ohio State University)
Cited by 29
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k
Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
|Journal of Clinical Oncology|1999|893